It is scheduled to meet experts from the “Centers for Disease Control and Prevention” of the US Department of Health, on Wednesday, to issue a recommendation on how to use the vaccine in that age group, and the vaccine may be available once the agency director approves the recommendation.
So far, the vaccine “Pfizer” and its partner, “Biontech”, are allowed to be given only to people 16 years and over.
In late March, Pfizer announced that it would ask the FDA to expand the permit for emergency use to allow young children to receive the vaccine, citing clinical trials that showed the vaccine elicits “excellent efficacy and strong antibody responses” in adolescents aged 12 years. To 15 years old.
The company plans to submit two new applications for emergency use licensing in September, with one application covering children ages two to five, and a second application applicable to children ages five to 11.